

# Board of Directors - Public

## SUMMARY

Meeting Date: 25 May 2022

Agenda Item: 12

<b>Report Title:</b>	<b>Financial Performance Report – for the period ending 31 March 2022</b>	
<b>Author(s):</b>	Matt White, Deputy Director of Finance	
<b>Accountable Director:</b>	Phillip Easthope, Executive Director of Finance, IMST & Performance	
<b>Other Meetings presented to or previously agreed at:</b>	<b>Committee/Group:</b>	Finance & Performance Committee
	<b>Date:</b>	12 May 2022
<b>Key Points recommendations to or previously agreed at:</b>	Routine reporting of financial performance. Currently no major risks or concerns other than the continued need to identify CIPs. Non-recurrent underspends to date driven by reduced Covid-19 Costs and delays in recruitment linked to MHIS investment and expansion.	

## Summary of key points in report

### Summary at March 2022:

- The Organisation wide surplus of £1.8m at the end of M12 (Mar 22), £2.2m favourable to plan. This is a £1.1m adverse movement on M11's underspend of £2.9m. The large movement is largely due to technical adjustments not originally in the forecast such as Gift of Time and other provisions.
- The position has moved favourably from £1.3m surplus that was reported in early draft documents. This is primarily due to a £443k gain on Local Authority pensions.
- MHIS spend rates continue to increase marginally each month. The total spend in 21-22 was £3.3m against an investment of £5.7m. Assuming current staff in post values the forecast spend in 23-24 will be £4.5m. This suggests there remains approximately £1.2m vacancies associated with MHIS funds.
- Covid underspend is £4.7m as expected. This is marginally lower than the forecast underspend of £4.8m.
- Agency and Out of Area Costs remain high risk. Total spend for the year on these areas is £15m which equates to 11% of the total organisational spend.
- Capital spend increased significantly in M12 and resulted in £8.2m being spent in 21-22 which is in line with the Organisations CDEL expectations.
- The Figures reported are pre-audit and while no adjustments are anticipated this should be noted.

The summary financial plan 2022/23 is contained at slide 12. This provides the basis of the plan considered and approved by the Board of Directors at their workshop on 27<sup>th</sup> April 2022.

Recommendation for the Board/Committee to consider:						
Consider for Action		Approval		Assurance	x	Information
The committee is asked to acknowledge that while 2021/22 CIP has been delivered non-recurrently due to overall underspend position, recurrent CIP delivery has been a significant challenge. There has been appropriate escalation in the conversation among the Executive, with a revised programme board approach being put in place. Pat Keeling will lead this process as SRO. Initial conversations and presentation with service leaders at Service Delivery Group took place on 6 April to improve ownership and accountability across the Trust and to further build on the work started by the CIP Working Group.						
Received and noted at the Finance & Performance Committee meeting held on 12 May 2022.						
Receive and formally approve the planned £2.7m deficit in the 2022/23 Financial Plan.						

Please identify which strategic priorities will be impacted by this report:						
Covid-19 Recovering Effectively			Yes	X	No	
CQC Getting Back to Good			Yes	X	No	
Transformation – Changing things that will make a difference			Yes	X	No	
Partnerships – working together to have a bigger impact			Yes		No	X
Is this report relevant to compliance with any key standards? State specific standard						
Care Quality Commission Fundamental Standards	Yes	X	No		<i>Regulation 17: Good Governance Regulation 13: Financial Position</i>	
Data Security & Protection Toolkit	Yes		No	X		
Any other specific standard	Yes		No	X		
Have these areas been considered? YES/NO				If Yes, what are the implications or the impact? If no, please explain why		
Service user and carer safety and Experience	Yes		No	X	<i>Out of scope</i>	
Financial (revenue &capital)	Yes	X	No		<i>Identification of financial sustainability risks</i>	
OD/Workforce	Yes		No	X	<i>Out of Scope</i>	
Equality, Diversity & Inclusion	Yes		No	X		
Legal	Yes		No	X	<i>Out of Scope</i>	

# Financial Performance Report

March 2022



<b>Contents</b>	<b>Slide/Page</b>
Executive Summary	<a href="#">3</a>
Financial Overview	<a href="#">4</a>
Forecast	<a href="#">5</a>
Risk & Recovery	<a href="#">6</a>
Covid	<a href="#">7</a>
Cost Improvement Programme	<a href="#">8</a>
Summary of Financial Position	<a href="#">9</a>
12 Months Cash Flow	<a href="#">10</a>
Capital Programme	<a href="#">11</a>



# Executive Summary

KPI	Annual Plan £'000	Year to Date Plan £'000	Year To Date Actual £'000
<b>Surplus/Deficit</b>	<b>0</b>	<b>0</b>	<b>1,811</b>
<b>Covid Expenditure</b>	<b>6,596</b>	<b>6,596</b>	<b>1,895</b>
<b>Agency</b>	<b>5,904</b>	<b>5,904</b>	<b>5,899</b>
<b>Cash</b>	<b>62,075</b>	<b>62,075</b>	<b>58,757</b>
<b>Efficiency Savings</b>	<b>2,650</b>	<b>2,650</b>	<b>2,650</b>
<b>Capital</b>	<b>8,197</b>	<b>8,197</b>	<b>8,191</b>
<b>Better Payments Practice Code</b>	<b>99.4% by Number</b>		
	<b>99.6% by Value</b>		

## Summary at March 2022:

- The Organisation wide surplus of £1.8m at the end of M12 (Mar 22), £2.2m favourable to plan. This is a £1.1m adverse movement on M11's underspend of £2.9m. The large movement is largely due to technical adjustments not originally in the forecast such as Gift of Time and other provisions.
- MHIS spend rates continue to increase marginally each month. The total spend in 21-22 was £3.3m against an investment of £5.7m. Assuming current staff in post values the forecast spend in 23-24 will be £4.5m. This suggests there remains approximately £1.2m vacancies associated with MHIS funds.
- Covid underspend is £4.7m as expected. This is marginally lower than the forecast underspend of £4.8m.
- Agency and Out of Area Costs remain high risk. Total spend for the year on these areas is £15m which equates to 11% of the total organisational spend.
- Capital spend increased significantly in M12 and resulted in £8.2m being spent in 21-22 which is in line with the Organisations CDEL expectations.
- The Figures reported are pre-audit and while no adjustments are anticipated this should be noted.

SPC Metrics	SPC Variation	SPC Target
Covid Costs	• L •	n/a
Agency Staff £	• H •	F
Out of Area £	• H •	F


SPC variation	
• • •	Common cause
• L •	Improvement - where low is good
• H •	Improvement - where high is good
• L •	Concern - where high is good
• H •	Concern - where low is good
• ? •	Special cause - where neither high nor low is good

SPC target	
?	Target Indicator – Pass/Fail
P	Target Indicator – Pass
F	Target Indicator – Fail

# Financial Overview

## MHIS Slippage

### MHIS YTD Spend



## Income & Expenditure Summary

	Year to Date				Forecast			
	Plan £'000	Actual £'000	Variance £'000	%	H2 Plan £'000	H2 Fcast £'000	H2 Variance £'000	%
	125,317	130,481	5,164	4%	125,317	130,481	5,164	4%
Clinical Income	19,976	21,368	1,392	7%	19,976	21,368	1,392	7%
<b>Total Income</b>	<b>145,293</b>	<b>151,849</b>	<b>6,556</b>	<b>5%</b>	<b>145,293</b>	<b>151,849</b>	<b>6,556</b>	<b>5%</b>
Pay	114,796	117,422	2,626	2%	114,796	117,422	2,626	2%
Non Pay	25,549	28,354	2,805	11%	25,549	28,354	2,805	11%
<b>Total Expenditure</b>	<b>140,345</b>	<b>145,776</b>	<b>5,431</b>		<b>140,345</b>	<b>145,776</b>	<b>5,431</b>	
Post EBITDA	6,235	5,653	(582)	(9%)	6,235	5,653	(582)	(9%)
<b>Net Surplus / (Deficit)</b>	<b>(1,287)</b>	<b>420</b>	<b>1,707</b>		<b>(1,287)</b>	<b>420</b>	<b>1,707</b>	
Technical Adjustments	1,287	1,391	104	8%	1,287	1,391	104	8%
<b>Adjusted Net Surplus / (Deficit)</b>	<b>0</b>	<b>1,811</b>	<b>1,811</b>		<b>0</b>	<b>1,811</b>	<b>1,811</b>	
<b>KPI's</b>								
Out of Town (OOT)	8,820	9,708	(888)	(10%)	9,563	9,708	(145)	(2%)
Agency	5,904	5,873	31	1%	7,434	5,873	1,561	21%
Covid	6,596	1,895	4,701	71%	6,596	1,895	4,701	71%
CIPs	2,650	2,650	0	0%	2,650	2,650	0	0%
See right for Directorate split								

## Summary at M12 March 2022:

- Operating **surplus of £1,811k (£1.8m)** at Month 12 (Month 11: £2,899k)
- Change to FOT mainly due to provision adjustments
- Increase in non-recurrent spend
- Agency and Out of Area placements remain risks to the Organisation's underlying position. See *Risks and Recovery* slide for detail.
- Low Covid spend and underspends against investments has driven Trust surplus position.
- High vacancy rate strengthening financial position. Estimated contribution for the year is £18m, partly offset by bank and agency use.
- Strong cash position (£59m)
- The Capital programme spend has met plan with an outturn of £8.2m
- The NHSI plan currently differs from the Ledger plan due to technical abnormalities employed by NHSI.
- Variance and Trust reporting is based on Ledger Plan and actual reported position.

## Directorate Year To Date Position

			GP					Central Budgets £'000	Central Reserves £'000
			Trust Wide £'000	Clinical £'000	Corporate £'000	Surgeries £'000	Medical £'000		
Pay	NHSI Plan	114,796	85,130	18,026	0	10,164	693	783	
		116,291	86,239	18,261	0	10,296	702	794	
		117,422	85,226	17,118	7	10,646	4,947	(521)	
		(1,131)	1,012	1,143	(7)	(350)	(4,244)	1,315	
Non Pay	Plan	25,549	14,312	13,015	0	1,796	(3,351)	(223)	
		22,916	12,837	11,674	0	1,611	(3,006)	(200)	
	Actual	28,354	20,054	9,922	(27)	1,379	(2,840)	(135)	
		(5,438)	(7,216)	1,752	27	232	(166)	(65)	



# Forecast

	Prior Year	Actual												Forecast		
		Out-turn			M12 Plan			Variance								
		£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income</b>																
Income from Patient Care Activities	118,174	10,072	9,691	10,586	10,296	10,219	12,110	10,296	10,274	10,442	10,389	10,506	15,600	130,481	125,317	5,164
Other Operating Income	35,537	1,726	1,579	1,634	1,711	1,723	1,511	1,633	1,800	1,736	1,802	2,280	2,233	21,368	19,976	1,392
<b>Total Income</b>	<b>153,711</b>	<b>11,798</b>	<b>11,270</b>	<b>12,220</b>	<b>12,007</b>	<b>11,942</b>	<b>13,621</b>	<b>11,929</b>	<b>12,074</b>	<b>12,178</b>	<b>12,191</b>	<b>12,786</b>	<b>17,833</b>	<b>151,849</b>	<b>145,293</b>	<b>6,556</b>
<b>Expenditure</b>																
Substantive	105,189	7,997	8,096	8,044	7,960	8,074	9,411	8,230	8,495	8,172	8,362	8,394	8,921	100,156	100,178	(22)
Bank	6,006	662	393	581	503	586	561	503	566	576	507	505	531	6,474	6,771	(297)
Agency	4,638	389	403	503	503	593	568	538	507	346	559	499	465	5,873	7,434	(1,561)
Other (Apprenticeship Levy)	411	38	39	39	38	39	13	34	35	34	34	33	4,543	4,919	413	4,506
<b>Total Pay</b>	<b>116,244</b>	<b>9,086</b>	<b>8,931</b>	<b>9,167</b>	<b>9,004</b>	<b>9,292</b>	<b>10,553</b>	<b>9,305</b>	<b>9,603</b>	<b>9,128</b>	<b>9,462</b>	<b>9,431</b>	<b>14,460</b>	<b>117,422</b>	<b>114,796</b>	<b>2,626</b>
Purchase of Healthcare	8,149	710	680	845	827	845	862	795	811	664	959	899	811	9,708	9,563	145
Drugs	850	75	75	74	83	76	90	73	80	79	83	89	89	965	939	26
Other non pay	18,011	972	960	1,271	1,325	1,162	1,224	1,383	1,178	1,684	1,461	1,529	3,532	17,681	15,047	2,634
<b>Total Non Pay</b>	<b>27,010</b>	<b>1,757</b>	<b>1,715</b>	<b>2,190</b>	<b>2,235</b>	<b>2,083</b>	<b>2,176</b>	<b>2,251</b>	<b>2,069</b>	<b>2,427</b>	<b>2,503</b>	<b>2,517</b>	<b>4,432</b>	<b>28,354</b>	<b>25,549</b>	<b>2,805</b>
<b>Total Expenditure</b>	<b>143,254</b>	<b>10,843</b>	<b>10,646</b>	<b>11,357</b>	<b>11,239</b>	<b>11,375</b>	<b>12,729</b>	<b>11,556</b>	<b>11,672</b>	<b>11,555</b>	<b>11,965</b>	<b>11,948</b>	<b>18,892</b>	<b>145,776</b>	<b>140,345</b>	<b>5,431</b>
<b>EBITDA</b>	<b>10,457</b>	<b>955</b>	<b>624</b>	<b>863</b>	<b>768</b>	<b>567</b>	<b>892</b>	<b>373</b>	<b>402</b>	<b>623</b>	<b>226</b>	<b>839</b>	<b>(1,059)</b>	<b>6,073</b>	<b>4,948</b>	<b>1,125</b>
<b>Post EBITDA</b>	<b>7,827</b>	<b>395</b>	<b>395</b>	<b>395</b>	<b>389</b>	<b>388</b>	<b>389</b>	<b>386</b>	<b>386</b>	<b>384</b>	<b>383</b>	<b>386</b>	<b>1,377</b>	<b>5,653</b>	<b>6,235</b>	<b>(582)</b>
<b>Net Surplus / (Deficit)</b>	<b>2,630</b>	<b>560</b>	<b>229</b>	<b>468</b>	<b>379</b>	<b>179</b>	<b>503</b>	<b>(13)</b>	<b>16</b>	<b>239</b>	<b>(157)</b>	<b>453</b>	<b>(2,436)</b>	<b>420</b>	<b>(1,287)</b>	<b>1,707</b>
Technical Adjustments	35	3	3	3	3	3	3	3	3	(24)	31	3	1,357	1,391	1,287	104
<b>Adjusted Net Surplus / (Deficit)</b>	<b>2,665</b>	<b>563</b>	<b>232</b>	<b>471</b>	<b>382</b>	<b>182</b>	<b>506</b>	<b>(10)</b>	<b>19</b>	<b>215</b>	<b>(126)</b>	<b>456</b>	<b>(1,079)</b>	<b>1,811</b>	<b>0</b>	<b>1,811</b>

### Commentary:



- The Organisational surplus at M12 of £1.8m is above revised H2 plans of £0m. This is largely driven by underspends against Covid funds and Investments.
- The non-recurrent underspends are partially offset by overspends in out of area placements and temporary staffing on in-patient wards.

# Risk & Recovery | Out of Area & Agency



## Out of Area:



- Full year spend of £9.7m (orange line adjacent graph).
- Contracts for 12 Acute Beds in place. This increases the SHSC bed base by 8 beds, when offsetting closures due to estates work are accounted for.
- Current levels expected to be remain into new financial year





## Agency:

- Full year spend of £5.9m (orange line adjacent graph)
- Outturn figures in line with plan
- While agency use has increased over the previous 12 months it should be considered that increased investments have increased vacancies and agency staff play a vital role in helping to cover these.
- Agency use will be a key area of focus for the Trust in the new financial year as it looks for efficiency savings

# Covid



- Covid spend remains low and the M12 Surplus of £4.8m matches plan
- Covid funds available in 22/23 will be significantly reduced. While they are forecast to be adequate to cover costs there will be minimal benefits realised from underspends as seen in the current financial year.
- Majority of monthly covid spend relates to staffing overtime costs.



# Cost Improvement Programme



Finance Report | March 2022

Directorate	Year to Date					Forecast Outturn					Scheme Status					
	Target	Delivery			Gap to Target	Target	Delivery			Gap to Target	Unidentified	Opportunity	Plans in Progress	Plan Identified	Total	
		R	NR	Total		£	£	£	£		£	£	£	£	£	
Central Management	30	30		30		30	30		30					30	30	
Acute & Community Services	795	87		87	709	795	87		87	709	709	5	82	795		
Rehab & Specialist Services	628	1	627	628		628	1	627	628				628	628		
Clinical Directorates	1,453	117	627	744	709	1,453	117	627	744	709	709	5	740	1,453		
Medical	38	38		38		38	38		38				38	38		
Corporate Governance	23	23		23		23	23		23				23	23		
Special Projects & Facilities	136	111	26	136		136	111	26	136			27	26	83	136	
Nursing & Professions	52	52		52		52	52		52				52	52		
People	49	17		17	32	49	17		17	32		32	12	5	49	
Finance	86	113		113	(28)	86	113		113	(28)		(28)		113	86	
Corporate	384	354	26	380	4	384	354	26	380	4		4	27	38	315	
Reserves	813		887	887	(74)	813		1,526	1,526	(713)		(713)		1,526	813	
<b>Grand Total</b>	<b>2,650</b>	<b>471</b>	<b>1,540</b>	<b>2,011</b>		<b>2,650</b>	<b>471</b>	<b>2,179</b>	<b>2,650</b>				<b>27</b>	<b>42</b>	<b>2,580</b>	<b>2,650</b>

- Majority of schemes delivered non-recurrently

# SOFP | Statement of Financial Position

	OPENING 2021/22	ACTUAL	MOVEMENT	YEAR END PLAN
	£'000	£'000	£'000	£'000
<b>Non-Current Assets</b>				
Property, Plant & Equipment (PPE)	57,810	55,238	(2,572)	49,384
Intangible Assets	1,062	1,364	302	1,998
Other Non-Current Assets	4,554	16,416	11,862	4,617
<b>Non-Current Assets Total</b>	<b>63,426</b>	<b>73,018</b>	<b>9,592</b>	<b>55,999</b>
<b>Current Assets</b>				
Receivables	3,541	6,855	3,314	7,699
Cash and Cash Equivalents	62,075	58,757	(3,318)	55,741
Other Current Assets	2,876	1,233	(1,643)	105
<b>Total Current Assets</b>	<b>68,492</b>	<b>66,845</b>	<b>(1,647)</b>	<b>63,545</b>
<b>Current Liabilities</b>				
Provisions	(613)	(863)	(250)	(704)
Payables	(8,580)	(8,215)	365	(10,694)
Other Current Liabilities	(5,204)	(5,711)	(507)	(29)
<b>Total Current Liabilities</b>	<b>(14,397)</b>	<b>(14,789)</b>	<b>(392)</b>	<b>(11,427)</b>
<b>Net Current Assets/ (Liabilities)</b>	<b>54,095</b>	<b>52,056</b>	<b>(2,039)</b>	<b>52,118</b>
Total Non-Current Liabilities	(6,039)	(6,552)	(513)	(5,441)
<b>Total Net Assets</b>	<b>111,482</b>	<b>118,522</b>	<b>7,040</b>	<b>102,676</b>
<b>Total Taxpayers Equity</b>	<b>111,482</b>	<b>115,376</b>	<b>3,894</b>	<b>102,676</b>



## STATEMENT OF FINANCIAL POSITION COMMENTARY

SHSC reports a positive cash position of £58.8 million to the end of March 2022. There are no working capital concerns, and the Better Payment Practice expectations are met monthly. The current ratio (current assets to current liabilities) is still 5:1, with cash contributing 88% of current assets.

The contract for the sale of Fulwood land was signed in December 2021 and £50k toward the contract was received in January 2022. Funds from the sale are expected to be reinvested in capital development and rebuilding SHSC's asset base over the next 3 years.

Liabilities present no concerns.

## HIGHLIGHTS FOR THE REMAINDER OF THE YEAR

Debt remains within expected levels. There is a concerted effort to improve collections especially for debts for overpayments to employees leaving SHSC.

High levels of invoices were raised in March due to year end. £5.5m of these are current.

## NET WORKING CAPITAL

At the end of March 2022 SHSC had a cash balance of £58.8 million compared to £59.5 million the previous month due to higher capital payments.

The Trust had a negative net working capital balance of £5,299k excluding cash (positive NWC of £64,056k including cash). This has been a stable trend over the last couple of months

The high liquidity ratio of 5:3 will give SHSC latitude to operate without the need to borrow to finance working capital. SHSC may be capable of financing the 5 years Capital Programme from internal funds if income from the sale of Fulwood land is released to fund the CDEL.


# 12 Months Cash Flow Forecast

	Prior Year Mar-21 £000s	Actual											
Cash flow as at February 2022	2021/22 Mar-21 £000s	2021/22 Apr-21 £000s	2021/22 May-21 £000s	2021/22 Jun-21 £000s	2021/22 Jul-21 £000s	2021/22 Aug-21 £000s	2021/22 Sep-21 £000s	2021/22 Oct-21 £000s	2021/22 Nov-21 £000s	2021/22 Dec-21 £000s	2021/22 Jan-22 £000s	2021/22 Feb-22 £000s	2021/22 Mar-22 £000s
Operating Surplus/(deficit)	3,898	560	229	467	377	182	503	(13)	16	238	(157)	463	(2,597)
Net cash generated from / (used in) operations	9,881	(102)	753	(663)	2,841	1,701	(2,188)	2,571	(633)	(1,280)	(1,057)	(350)	2,996
Net cash inflow/(outflow) from investing activities, Total	(5,574)	(2,310)	(134)	(542)	(604)	(177)	(761)	(673)	(694)	(693)	(447)	(330)	(1,210)
Net cash inflow/(outflow) before financing	8,205	(1,852)	848	(738)	2,614	1,706	(2,446)	1,885	(1,311)	(1,735)	(1,661)	(217)	(811)
Net Cash inflow/(outflow) from financing activities, Total	2,852	139	1	(4)			(807)		1,029		(4)	(7)	52
Increase/(decrease) in cash and cash equivalents	11,057	(1,713)	849	(742)	2,614	1,706	(3,253)	1,885	(282)	(1,735)	(1,665)	(224)	(759)
Cash and cash equivalents at start of period	51,018	62,075	60,363	61,212	60,470	63,084	64,790	61,537	63,422	63,140	61,405	59,740	59,516
Increase/(decrease) in cash and cash equivalents	11,057	(1,713)	849	(742)	2,614	1,706	(3,253)	1,885	(282)	(1,735)	(1,665)	(224)	(759)
Cash and cash equivalents at end of period	62,075	60,363	61,212	60,470	63,084	64,790	61,537	63,422	63,140	61,405	59,740	59,516	58,757

## NARRATIVE

The Trust has a capital programme of £8,197k to deliver before the end of the financial year. Part of the capital (£1,614k) will be funded through the Department of Health and Social Care programme for dormitory replacements, cyber security, and electronic patients records programmes. £6,583k will be funded internally.

The cash forecast was revised in line with trends so far to £59,989k by 31 March 2022. This is due to expected capital cash out before the end of the financial year.



# Capital Programme

## CAPITAL FORECAST 2020/21 TO 2025/26


Category	2021/22		2022/23		2023/24		2024/25		2025/26		Total Programme Forecast	
	YTD £000	Revised Plan £000	Plan £000	Plan £000	Plan £000	Plan £000	Plan £000	Plan £000	Plan £000	Plan £000		
Therap/Com	29	-	150	26,901	29,856	36,000					92,907	
EPR	301	300	2,848	2,136	1,107	-					6,391	
Buildings	7,224	6,695	6,118	5,428	3,940	2,942					25,123	
Transport	298	280	470	-	-	-					750	
Equipment	51	50	50	50	50	50					250	
IMST	288	872	864	430	342	-					2,508	
<b>Total</b>	<b>8,191</b>	<b>8,197</b>	<b>10,500</b>	<b>34,945</b>	<b>35,295</b>	<b>38,992</b>					<b>127,929</b>	

Capital expenditure is <85% or >115% of plan for year to date

## POSITION SUMMARY 2021/22

Capital Position to Date	Revised Plan	Actual	Variance
In-month spend	1,713	2,489	776 RED
Cumulative spend	8,197	8,191	(6) Green
Capital expenditure is <85% or >115% of plan for year to date			Green
Capital Forecast Outturn	Revised Plan	Actual	Variance
Cumulative spend	8,197	8,191	(6) Green
Capital expenditure is <85% or >115% of plan for year to date			Green

## CAPITAL PROJECT PORTFOLIO - YEAR TO DATE POSITION



## NARRATIVE

The capital plan for 2021/22 was revised in October 2021 to accommodate a £877k request from the Integrated Care Services Partnership (ICS) to support the partnership CDEL system. SHSC received additional funding for Cyber Security (£190k) and Electronic Patients Records (£300k) which increased the Capital plan to £8,197k. Other new projects were included in the programme to cover small slippages caused by delays in implementation and covid.

At the end of March 2022, SHSC is reporting capital expenditure including accruals of £8,191k, which is £6k below the annual plan.

# Financial Plan 2022/23 summary

The Board of Directors discussed and approved the financial plan at its 27<sup>th</sup> April 2022 workshop, summary details are below.

## Income and Expenditure plan

Statement of comprehensive income	£'000
Operating income from patient care activities	122,191
Other operating income	22,002
Employee expenses	- 117,651
Operating expenses excluding employee expenses	- 27,460
<b>OPERATING SURPLUS/(DEFICIT)</b>	<b>- 918</b>
<b>FINANCE COSTS</b>	
PDC dividends payable/refundable	- 1,800
<b>NET FINANCE COSTS</b>	<b>- 1,800</b>
<b>SURPLUS/(DEFICIT) FOR THE PERIOD/YEAR</b>	<b>- 2,718</b>

Deficit plan of £2.7m requires delivery of £3.5m CIP, i.e. zero delivery would result in a deficit of £6.2m.

## Break-even consideration

The paper set out our statutory responsibility to break-even, which would minimally require £6.2m CIP. This was acknowledged, including likely further discussions at a system and national level but that would represent a significant challenge of c5% including internal investment. This would represent a significant risk and one we don't have sufficient quality and equality impact assessed plans even at outline stage to be assured this is deliverable.

## Capital plan

Funding	22/23	23/24	24/25	25/26	26/27
CDEL	7,302	1,705	1,189	992	932
External / Additional PDC	3,198	33,240	34,106	38,000	-
<b>Total</b>	<b>10,500</b>	<b>34,945</b>	<b>35,295</b>	<b>38,992</b>	<b>932</b>

The capital plan meets the allocated Capital Departmental Expenditure Limit (CDEL). For 22/23 the external / additional PDC requirement relates to the electronic patient record system. Funding was approved and received last year and we are awaiting confirmation this year as per the approved business case. This is considered low risk.

The summary long term financial model (LTFM) outputs below show marginally increased deficit, if unmitigated would dilute cash reserves by £11.9m to March 26. The current cash balance of £58.m is sufficient to meet our operational and capital (CDEL) requirements.

	Forecast	Forecast	Forecast	Forecast	Forecast
	Mar - 22	Mar - 23	Mar - 24	Mar - 25	Mar - 26
Income	146,440	143,621	146,206	148,838	151,517
Expenditure	- 143,496	- 144,537	- 146,993	- 149,414	- 151,605
Operating Surplus / (Deficit)	2,944	- 916	- 786	- 575	- 87
Non-Operating expenses	- 1,676	- 1,800	- 2,193	- 2,538	- 3,036
Surplus / (Deficit)	1,268	- 2,716	- 2,979	- 3,113	- 3,123

The LTFM requires updating to reflect small changes to the plan pre submission. The minor changes to I&E are deemed insignificant. E.g. £2k change to deficit.

## Actions

Approve plan of £2.7m deficit

Acknowledge our current planned deficit and system deficit of £85m will be scrutinised post submission and further work may be required.